Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
aTYR PHARMA INC (LIFE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD expected to initiate in the third quarter of 2023. Ended the second quarter of 2023 with $112.0 million in cash, cash equivalents and investments. SAN DIEGO – August 9, 2023 – aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2023 results and provided a corporate update. “Throughout the second quarter we have continued to progress and invest in our clinical development program for our lead therapeu..."
05/09/2023 8-K Quarterly results
Docs: "aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to initiate in the third quarter of 2023. Company to host multiple presentations for efzofitimod at the upcoming American Thoracic Society 2023 International Conference. February follow-on common stock offering generated $48.1 million in net proceeds. Ended the first quarter 2023 with $117.6 million in cash, cash equivalents and investments. SAN DIEGO – May 9, 2023 – aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA s..."
03/09/2023 8-K Quarterly results
Docs: "aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to begin in 2023. February 2023 follow-on common stock offering of approximately $52.0 million in gross proceeds. Company to host conference call and webcast today, March 9th, at 5:00 p.m. EST / 2:00 p.m. PST. SAN DIEGO – March 9, 2023 – aTyr Pharma, Inc. , a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2022 results and provided a corporate update. “2022 was..."
11/10/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/14/2022 8-K Quarterly results
Docs: "Cash & Investment Position: Cash, cash equivalents and investments as of December 31, 2021, were $107.9 million. 2 • R&D Expenses: Research and development expenses were $23.3 million for the year ended 2021, which consisted primarily of product development costs for the efzofitimod and ATYR2810 programs. Program costs for efzofitimod included preparation for the upcoming planned registrational trial in pulmonary sarcoidosis, which included the manufacture of clinical trial material and initiation of technology transfer activities with FUJIFILM Diosynth Biotechnologies. Program costs for ATYR2810 included costs related to IND-enabling activities and the initiation of manufacturing activities with Lonza. ● G&A Expenses: General and administrative expenses were $10.8 million for the ye..."
11/10/2021 8-K Quarterly results
Docs: "Cash & Investment Position: Cash, cash equivalents and investments as of September 30, 2021 were $116.4 million. ● R&D Expenses: Research and development expenses were $5.1 million for the third quarter of 2021, which consisted primarily of product development costs for ATYR1923 and ATYR2810 programs. ● G&A Expenses: General and administrative expenses were $2.6 million for the third quarter of 2021. ● Shares Outstanding: Commons shares outstanding were 27,790,677 as of September 30, 2021. 3 Conference Call and Webcast Details aTyr will host a conference call and webcast today at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to discuss its financial results and provide a corporate update. Interested parties may access the call by dialing toll-free 844-358-9116 from the ..."
08/10/2021 8-K Quarterly results
Docs: "Cash & Investment Position: Cash, cash equivalents and investments as of June 30, 2021 were $44.1 million. ● R&D Expenses: Research and Development expenses were $7.7 million for the second quarter of 2021, which consisted primarily of ATYR1923 and ATYR2810 program costs. ● G&A Expenses: General and administrative expenses were $2.8 million for the second quarter of 2021. ● Shares Outstanding: Commons shares outstanding were 16,919,872 as of August 9, 2021. Conference Call and Webcast Details aTyr will host a conference call and webcast today at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to discuss its financial results and provide a corporate update. Interested parties may access the call by dialing toll-free 844-358-9116 from the US, or 209-905-5951 internationally..."
05/13/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Third Quarter 2020 Financial Results"
08/13/2020 8-K Quarterly results
05/12/2020 8-K Quarterly results
03/26/2020 8-K Quarterly results
Docs: "aTyr Pharma Announces Fourth Quarter and Full Year 2019 Results and Provides Corporate Update Company to host conference call and webcast today at 5:00 p.m. EDT / 2:00 p.m. PDT"
11/14/2019 8-K Quarterly results
08/14/2019 8-K Quarterly results
Docs: "Press Release of aTyr Pharma, Inc."
05/13/2019 8-K Quarterly results
Docs: "aTyr Pharma Announces First Quarter 2019 Results and Provides Corporate Update Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients ongoing"
03/25/2019 8-K Quarterly results
Docs: "aTyr Pharma Announces Fourth Quarter and Full Year 2018 Results and Provides Corporate Update Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients initiated in December 2018"
11/13/2018 8-K Quarterly results
Docs: "aTyr Pharma Announces Third Quarter 2018 Operating Results and Provides Corporate Update - Initiation of Proof-of-Concept Study in Patients with Pulmonary Sarcoidosis Planned for Fourth Quarter of 2018 -"
05/14/2018 8-K Quarterly results
Docs: "aTyr Pharma Announces First Quarter 2018 Operating Results, Program Prioritization and Corporate Restructuring -Conference Call Today at 8:00 am E.T./5:00 a.m. P.T. -"
03/19/2018 8-K Quarterly results
Docs: "3 ATYR PHARMA INC. Condensed Consolidated Statements of Operations"
08/14/2017 8-K Quarterly results
Docs: "Safety Extension Study Results – aTyr recently completed two extension studies in patients with limb-girdle muscular dystrophy 2B , adult facioscapulohumeral muscular dystrophy , and early onset FSHD. Per protocol patients received 3.0 mg/kg of Resolaris weekly in these extension studies. o No significant adverse events or observed signs of general immunosuppression in either study. o Across both studies, 12 patients received at least six months of Resolaris in each study with no significant trends of worsening in either manual muscle testing or individualized neuromuscular quality of life assessment scores: ▪ 5 of 10 patients remained stable or improved their MMT score at 24 weeks; 3 of 6 patients remained stable or improved their MMT score at 36 weeks. o In the 006 trial, which com..."
05/11/2017 8-K Form 8-K - Current report
03/16/2017 8-K Quarterly results
Docs: "Adult LGMD2B Patients – Ten adult LGMD2B patients were administered Resolaris in an intra-patient, dose-escalation Phase 1b/2 clinical trial. 78% of the LGMD patients showed an improvement in their muscle function. In this open-label trial aTyr observed that LGMD2B patients showed greater signals of muscle improvement compared to those seen with FSHD patients. • Adult FSHD Patients – aTyr announced data from three separate clinical trials treating adult FSHD patients with Resolaris in 2016. Approximately 50% of patients demonstrated an increase in muscle function consistent over multiple studies. In addition, a small decrease in disease burden, as measured by the Individualized 1 Neuromuscular Quality of Life assessment, was observed in a majority of FSHD patients administered Resol..."
11/14/2016 8-K Quarterly results
Docs: "Fast Track Designation – In October, Resolaris was granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of FSHD, making it the first known therapeutic candidate for the treatment of FSHD to receive the designation. • World Muscle Society Presentation on Resolaris for FSHD – In October, aTyr presented clinical data from its adult FSHD trial at the 21st International Annual Congress of the World Muscle Society in Granada, Spain. The presentation included detailed data covering the safety, tolerability and pharmacokinetics of Resolaris, and further detailed activity seen in the patient-reported outcomes, known as the Individualized Neuromuscular Quality of Life Assessment , and the physician-reported functional assessment of Manual Muscle Testing . ..."
08/10/2016 8-K Form 8-K - Current report
05/11/2016 8-K Form 8-K - Current report
11/10/2015 8-K Form 8-K - Current report
08/12/2015 8-K Form 8-K - Current report
06/18/2015 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy